Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with single ventricle anatomy undergo staged surgical palliation. The result is an "in series" circulation with pulmonary blood flow and cardiac output directly related to pulmonary vascular resistance. While surgical outcomes have improved, the physiology of the single ventricle palliation results in continued long term attrition. Elevated pulmonary vascular resistance and impaired systemic ventricular function are important risk factors for failure of single ventricle palliation.
Sildenafil is a pulmonary vasodilator and has been shown to improve cardiac contractility in the pressure overloaded right ventricle.
The investigators will assess the safety, pharmacokinetics and hemodynamic efficacy of sildenafil in single ventricle patients following stage II and III surgical palliation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sildenafil | Active Comparator | Pharmacokinetic and hemodynamic evaluation following sildenafil administration |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sildenafil by injection | Drug | Sildenafil 0.125mg/kg injection over 20min |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Sildenafil Plasma Concentration | Assessment of peak sildenafil plasma concentration. | 5 minutes after completion of sildenafil infusion |
| Measure | Description | Time Frame |
|---|---|---|
| Hemodynamic Safety and Efficacy | Assessment of pulmonary vascular resistance | 10 minutes after completion of sildenafil infusion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
History of serious adverse event related to sildenafil administration.
History of sildenafil exposure within 48 hours of the study.
Presence of pulmonary venous obstruction.
Treatment with organic nitrates or alpha blockade therapy.
Contraindication to cardiac catheterization as determined by the attending cardiologist and including:
Renal failure defined as serum creatinine > 2 times higher than the upper limit of normal.
Liver dysfunction defined as alanine aminotransferase or aspartate aminotransferase > 3 times higher than the upper limit of normal.
Thrombocytopenia defined as a platelet count < 50 000 cells/µL.
Leukopenia defined as white blood cells < 2500 cells/µL.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kevin D Hill, MD | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23823195 | Result | Hill KD, Tunks RD, Barker PC, Benjamin DK Jr, Cohen-Wolkowiez M, Fleming GA, Laughon M, Li JS. Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med. 2013 Jul;14(6):593-600. doi: 10.1097/PCC.0b013e31828aa5ee. | |
| 24201857 | Derived | Tunks RD, Barker PC, Benjamin DK Jr, Cohen-Wolkowiez M, Fleming GA, Laughon M, Li JS, Hill KD. Sildenafil exposure and hemodynamic effect after Fontan surgery. Pediatr Crit Care Med. 2014 Jan;15(1):28-34. doi: 10.1097/PCC.0000000000000007. |
Not provided
Not provided
Enrolled subjects were excluded from trial participation if they demonstrated baseline hemodynamics suggesting that they would not tolerate sildenafil infusion (e.g. baseline hypotension)
Patients recruited upon presentation for elective Pre-stage II or stage III catheterization. The first patient was recruited on 4/14/2011 and the final patient was enrolled on 11/29/2012
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Baseline/Sildenafil | Assessment of baseline hemodynamics followed by sildenafil infusion with repeat assessment of hemodynamics |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Overall 21 subjects were enrolled and all subjects received a baseline assessment followed by sildenafil administration.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Sildenafil | Pharmacokinetic and hemodynamic evaluation following sildenafil administration Sildenafil by injection : Sildenafil 0.45mg/kg by injection over 20min Sildenafil by injection : Sildenafil 0.25mg/kg injection over 20min Sildenafil by injection : Sildenafil 0.35mg/kg by injection over 20min Sildenafil by injection : Sildenafil 0.125mg/kg injection over 20min |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Maximum Sildenafil Plasma Concentration | Assessment of peak sildenafil plasma concentration. | 3 patients were enrolled in this group but in 1 participant, an inadequate plasma sample volume prevented accurate determination of sildenafil concentration. | Posted | Mean | Standard Deviation | ng/mL | 5 minutes after completion of sildenafil infusion |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dose = 0.125mg/kg | Subjects receiving a sildenafil dose of 0.125mg/kg IV over 20 min |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Kevin Hill | Duke University Medical Center | 919-668-8305 | kevin.hill@duke.edu |
Not provided
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D018636 | Hypoplastic Left Heart Syndrome |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D006330 | Heart Defects, Congenital |
| D018376 | Cardiovascular Abnormalities |
| D000013 | Congenital Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068677 | Sildenafil Citrate |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013450 | Sulfones |
| D013457 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sildenafil by injection | Drug | Sildenafil 0.25mg/kg injection over 20min |
|
|
| Sildenafil by injection | Drug | Sildenafil 0.35mg/kg by injection over 20min |
|
|
| Sildenafil by injection | Drug | Sildenafil 0.45mg/kg by injection over 20min |
|
|
| Participants |
|
| Age Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | Peak Sildenafil Level (ng/mL) for Dose = 0.45mg/kg | Maximum sildenafil plasma concentration measured 5 minutes after completion of sildenafil infusion |
| OG003 | Peak Sildenafil Level (ng/mL) for Dose = 0.25mg/kg | Maximum sildenafil plasma concentration measured 5 minutes after completion of sildenafil infusionplasma concentration |
|
|
| Secondary | Hemodynamic Safety and Efficacy | Assessment of pulmonary vascular resistance | Posted | Median | Inter-Quartile Range | Wood units * m^2 | 10 minutes after completion of sildenafil infusion |
|
|
|
| 0 |
| 3 |
| 0 |
| 3 |
| EG001 | Dose = 0.25mg/kg | Subjects receiving a sildenafil dose of 0.25mg/kg IV over 20 min | 0 | 5 | 0 | 5 |
| EG002 | Dose = 0.35mg/kg | Subjects receiving a sildenafil dose of 0.35mg/kg IV over 20 min | 0 | 8 | 0 | 8 |
| EG003 | Dose = 0.45mg/kg | Subjects receiving a sildenafil dose of 0.45mg/kg IV over 20 min | 0 | 5 | 0 | 5 |
Not provided
Not provided
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| Sulfur Compounds |
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |